Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
This double-blind randomized placebo-controlled clinical trial will be done with the aim of oleoylethanolamide (OEA) supplementation on the SIRT1, AMPK, PGC1-α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes expression, and serum levels of IL-6, IL-10, and NRG-4, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD).
This double-blind randomized placebo-controlled clinical trial will be done with the aim of oleoylethanolamide (OEA) supplementation on the SIRT1, AMPK, PGC1-α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes expression, and serum levels of IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD).
This double-blind randomized placebo-controlled clinical trial will be done with the aim of oleoylethanolamide (OEA) supplementation on the SIRT1, AMPK, PGC1-α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes expression, and serum levels of IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD).
مطالعه کار آزمایی بالینی تصادفی کنترل دار دوسوکور حاضر با هدف تاثیرمکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و NRG-4 و ترکیب بدنی در بیماران مبتلا به کبد چرب غیر الکلی چاق (NAFLD) انجام خواهد شد. .
مطالعه کار آزمایی بالینی تصادفی کنترل دار دوسوکور حاضر با هدف تاثیرمکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4 و ترکیب بدنی در بیماران مبتلا به کبد چرب غیر الکلی چاق (NAFLD) انجام خواهد شد. .
مطالعه کار آزمایی بالینی تصادفی کنترل دار دوسوکور حاضر با هدف تاثیرمکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4 و ترکیب بدنی در بیماران مبتلا به کبد چرب غیر الکلی چاق (NAFLD) انجام خواهد شد. .
The body composition percentage
The expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes
serum levels of IL-6 and IL-10
The body composition percentage
The expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes
serum levels of IL-6. IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4
The body composition percentage The expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes serum levels of IL-6 and. IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4
درصد ترکیب بدن
میزان بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10
سطوح سرمی IL-6 و IL-10 و NRG-4
درصد ترکیب بدن
میزان بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10
سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4
درصد ترکیب بدن میزان بیان ژنهای SIRT1 و AMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP-β و IL-6 و IL-10 سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4
General information
To add the effects of oleoylethanolamide (OEA) supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, and CEBP- β genes and serum NRG4 levels.
To add the effects of oleoylethanolamide (OEA) supplementation on the serum levels of hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, and ox-LDL
To add the effects of oleoylethanolamide (OEA) supplementation on the expressionserum levels of SIRT1hs-CRP, AMPKIL-1β, PGC-1α, PPAR-γ, CEBPTNF-α, and CEBPTAC, GSH- β genesPx, SOD, catalase, MDA, and serum NRG4 levels.ox-LDL
اضافه کردن بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای AMPK، SIRT1
CEBP- β , CEBP-α، PPAR-γ، PGC-1α و سطوح سرمی NRG-4
اضافه کردن بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر سطوح سرمی hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL
اضافه کردن بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای AMPK، SIRT1 CEBP- β , CEBP-α، PPAR-γ، PGC-1α و سطوح سرمی NRGhs-4CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL
Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 وAMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP- β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و NRG-4 و ترکیب بدنی در بیماران بزرگسال مبتلا به کبد چرب غیر الکلی چاق (NAFLD)
بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 وAMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP- β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4 و ترکیب بدنی در بیماران بزرگسال مبتلا به کبد چرب غیر الکلی چاق (NAFLD)
بررسی تاثیر مکمل یاری اولئیل اتانول آمید (OEA) بر بیان ژنهای SIRT1 وAMPK و PGC-1α و PPAR-γ و CEBP-α و CEBP- β و IL-6 و IL-10 و سطوح سرمی IL-6 و IL-10 و hs-CRP و IL-1β و TNF-α و TAC و GSH-Px و SOD و کاتالاز و MDA و ox-LDL و NRG-4 و ترکیب بدنی در بیماران بزرگسال مبتلا به کبد چرب غیر الکلی چاق (NAFLD)
Ethics committees
#1
empty
2022-07-31, 1401/05/09
2022-07-31 00:00:00
empty
IR.TBZMED.REC.1401.425
IR.TBZMED.REC.1401.425
Primary outcomes
#1
empty
Serum levels of hs-CRP
Serum levels of hs-CRP
empty
سطوح سرمی hs-CRP
سطوح سرمی hs-CRP
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By laboratory ELISA kits
By laboratory ELISA kits
empty
کیت الایزا
کیت الایزا
#2
empty
Serum levels of IL-1β
Serum levels of IL-1β
empty
سطوح سرمی IL-1β
سطوح سرمی IL-1β
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By laboratory ELISA kits
By laboratory ELISA kits
empty
کیت الایزا
کیت الایزا
#3
empty
Serum levels of TNF-α
Serum levels of TNF-α
empty
سطوح سرمی TNF-α
سطوح سرمی TNF-α
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By laboratory ELISA kits
By laboratory ELISA kits
empty
کیت الایزا
کیت الایزا
#4
empty
Levels of total antioxidant capacity (TAC)
Levels of total antioxidant capacity (TAC)
empty
سطوح ظرفیت تام آنتی اکسیدانی (TAC)
سطوح ظرفیت تام آنتی اکسیدانی (TAC)
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By colorimetric method using Randox total antioxidant status kit
By colorimetric method using Randox total antioxidant status kit
empty
با استفاده از روش کالری متریک و کیت Randox total antioxidant status
با استفاده از روش کالری متریک و کیت Randox total antioxidant status
#5
empty
Levels of glutathione peroxidase (GSH-Px)
Levels of glutathione peroxidase (GSH-Px)
empty
سطوح گلوتاتیون پراکسیداز (GSH-Px)
سطوح گلوتاتیون پراکسیداز (GSH-Px)
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By spectrophotometric method using Ransel and Ransod kits
By spectrophotometric method using Ransel and Ransod kits
empty
با استفاده از روش اسپگتروفوتومتری و کیت Ransel and Ransod
با استفاده از روش اسپگتروفوتومتری و کیت Ransel and Ransod
#6
empty
Levels of superoxide dismutase (SOD)
Levels of superoxide dismutase (SOD)
empty
سطوح سوپراکسید دیسموتاز (SOD)
سطوح سوپراکسید دیسموتاز (SOD)
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By spectrophotometric method using Ransel and Ransod kits
By spectrophotometric method using Ransel and Ransod kits
empty
با استفاده از روش اسپگتروفوتومتری و کیت Ransel and Ransod
با استفاده از روش اسپگتروفوتومتری و کیت Ransel and Ransod
#7
empty
Level of malondialdehyde (MDA)
Level of malondialdehyde (MDA)
empty
سطوح مالون دی آلدهید (MDA)
سطوح مالون دی آلدهید (MDA)
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By the spectrophotometric thiobarbituric acid reactive substances (TBARS) method
By the spectrophotometric thiobarbituric acid reactive substances (TBARS) method
empty
با استفاده از روش spectrophotometric thiobarbituric acid reactive substances (TBARS)
با استفاده از روش spectrophotometric thiobarbituric acid reactive substances (TBARS)
#8
empty
Levels of catalase activity
Levels of catalase activity
empty
سطوخ فعالیت کاتالاز
سطوخ فعالیت کاتالاز
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By Aebi's method
By Aebi's method
empty
با استفاده از روش Aebi's
با استفاده از روش Aebi's
#9
empty
Serum levels of oxidized-low density lipoprotein (ox-LDL)
Serum levels of oxidized-low density lipoprotein (ox-LDL)
empty
سطوح سرمی لیپوپروتئین با چگالی پایین اکسید شده (ox-LDL)
سطوح سرمی لیپوپروتئین با چگالی پایین اکسید شده (ox-LDL)
empty
before intervention, and 3 months after intervention
before intervention, and 3 months after intervention
empty
قبل مداخله و سه ماه پس از شروع مداخله
قبل مداخله و سه ماه پس از شروع مداخله
empty
By laboratory ELISA kits
By laboratory ELISA kits
empty
کیت الایزا
کیت الایزا
Protocol summary
Study aim
This double-blind randomized placebo-controlled clinical trial will be done with the aim of oleoylethanolamide (OEA) supplementation on the SIRT1, AMPK, PGC1-α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes expression, and serum levels of IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD).
Design
This study will be done on sixty obese patients of both genders with NAFLD.
Settings and conduct
The study will be conducted in the nutrition faculty of Tabriz University of Medical Sciences and supplementation duration will be 12 weeks. The OEA and placebo sachets will be coded by the person responsible for preparing them, and the main investigators and the patients will be blinded to the type of the supplement each group receives.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Body mass index 30 to 40 kg/m2, and non-alcoholic fatty liver disease
Exclusion criteria: Use of drugs and supplements. smoking, pregnancy, breastfeeding, menopause, liver, kidney and gastrointestinal diseases, diabetes, heart failure, thyroid disorders
Intervention groups
patients in the OEA group will use two125 mg OEA capsules daily. In the placebo group, two 125 mg capsules of starch will be consumed daily.
Main outcome variables
The body composition percentage
The expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP-β, IL-6, and IL-10 genes
serum levels of IL-6. IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4
General information
Reason for update
To add the effects of oleoylethanolamide (OEA) supplementation on the serum levels of hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, and ox-LDL
Acronym
IRCT registration information
IRCT registration number:IRCT20090609002017N32
Registration date:2018-08-11, 1397/05/20
Registration timing:prospective
Last update:2022-09-06, 1401/06/15
Update count:2
Registration date
2018-08-11, 1397/05/20
Registrant information
Name
Alireza Ostadrahimi
Name of organization / entity
Tabriz University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 41 1335 7580
Email address
ostadrahimi@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-04-21, 1398/02/01
Expected recruitment end date
2020-01-21, 1398/11/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
Public title
Assessment of Oleoylethanolamide supplementation in prevention and treatment of non-alcoholic fatty liver disease
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Ages between 20 to 50 years
body mass index (BMI) 30 to 40 kg/m2
Diagnosis of non-alcoholic fatty liver disease by a liver specialist based on ultrasound
Exclusion criteria:
Regular use of nonsteroidal anti-inflammatory agents (NSAIDs) and antibiotics
Use of hepatotoxic drugs such as phenytoin, amiodarone, levothyroxine, amoxifene, lithium
Use of antihypertensive drugs
Using weight loss and lipid-lowering drugs
Use of probiotic and prebiotic supplements; vitamins; minerals; antioxidants; and omega 3 supplements in the last 3 months
Smoking
Pregnancy
Breast-feeding
Menopause
Pathological conditions affecting the liver such as viral hepatitis, acute or chronic hepatic impairment, liver transplantation, acute systemic disease
Gastrointestinal diseases
Diabetes
Heart failure
Thyroid disorders
Kidney Diseases
Haemochromatosis
Wilson's disease
Alpha-1 antitrypsin deficiency
Autoimmune diseases
Age
From 20 years old to 50 years old
Gender
Both
Phase
N/A
Groups that have been masked
Participant
Investigator
Outcome assessor
Sample size
Target sample size:
60
Randomization (investigator's opinion)
Randomized
Randomization description
Samples are assigned to intervention and control groups using simple random design
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, the main investigator and patients will be blind (oleoylethanolamide or placebo) .
The person responsible for preparing the supplement sachets (who is completely unrelated to the study) will be asked to assign a three digit code to each of the two powders (oleoylethanolamid and placebo), and keep the codes for himself until the end of the study and data analyses.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics Committee Tabriz University of Medical Sciences
Street address
Third Floor, Central Building (2), Tabriz University of Medical Sciences, Golghasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
00984133344280
Approval date
2018-05-21, 1397/02/31
Ethics committee reference number
IR.TBZMED.REC.1397.176
2
Ethics committee
Name of ethics committee
Ethics Committee Tabriz University of Medical Sciences
Street address
Third Floor, Central Building (2), Tabriz University of Medical Sciences, Golghasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
00984133344280
Approval date
2020-12-28, 1399/10/08
Ethics committee reference number
IR.TBZMED.REC.1399.908
3
Ethics committee
Name of ethics committee
Ethics Committee Tabriz University of Medical Sciences
Street address
Third Floor, Central Building (2), Tabriz University of Medical Sciences, Golghasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
00984133344280
Approval date
2022-07-31, 1401/05/09
Ethics committee reference number
IR.TBZMED.REC.1401.425
Health conditions studied
1
Description of health condition studied
Non-alcoholic fatty liver disease
ICD-10 code
K76.0
ICD-10 code description
Fatty (change of) liver, not elsewhere classified
Primary outcomes
1
Description
gene expression of IL-6
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
2
Description
gene expression of IL-10
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time- PCR
3
Description
Serum levels of IL-6
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By laboratory ELISA kits
4
Description
Serum levels of IL-10
Timepoint
Before intervention, and 3months after intervention
Method of measurement
By laboratory ELISA kits
5
Description
Serum levels of NRG-4
Timepoint
Before intervention, and 3months after intervention
Method of measurement
By laboratory ELISA kits
6
Description
gene expression of SIRT1
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
7
Description
gene expression of AMPK
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
8
Description
gene expression of PGC-1α
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
9
Description
gene expression of PPAR-γ
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
10
Description
gene expression of CEBP-α
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
11
Description
gene expression of CEBP-β
Timepoint
before intervention, and 3 months after intervention
Method of measurement
Real time-PCR
12
Description
Serum levels of hs-CRP
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By laboratory ELISA kits
13
Description
Serum levels of IL-1β
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By laboratory ELISA kits
14
Description
Serum levels of TNF-α
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By laboratory ELISA kits
15
Description
Levels of total antioxidant capacity (TAC)
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By colorimetric method using Randox total antioxidant status kit
16
Description
Levels of glutathione peroxidase (GSH-Px)
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By spectrophotometric method using Ransel and Ransod kits
17
Description
Levels of superoxide dismutase (SOD)
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By spectrophotometric method using Ransel and Ransod kits
18
Description
Level of malondialdehyde (MDA)
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By the spectrophotometric thiobarbituric acid reactive substances (TBARS) method
19
Description
Levels of catalase activity
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By Aebi's method
20
Description
Serum levels of oxidized-low density lipoprotein (ox-LDL)
Timepoint
before intervention, and 3 months after intervention
Method of measurement
By laboratory ELISA kits
Secondary outcomes
1
Description
Body composition
Timepoint
Before intervention, and 3 months after intervention
Method of measurement
Measurement of body composition, including fat mass, fat free mass and total body water determination using bioelectrical impedance analyser (BIA)
Intervention groups
1
Description
Intervention group: daily 2 capsules including 125 mg oleoylethanolamide
Category
Prevention
2
Description
Control group: daily 2 capsules including 125 mg placebo
Category
Prevention
Recruitment centers
1
Recruitment center
Name of recruitment center
Health centers of Tabriz University of Medical Sciences
Full name of responsible person
Alireza Ostadrahimi
Street address
Attar Neyshabouri Street, Golgasht Avenue, Nutrition faculty, Tabriz University of Medical Science, Ground Floor
City
Tabriz
Province
East Azarbaijan
Postal code
5166614711
Phone
+98 41 3335 7580
Email
ostadrahimi@tbzmed.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Vice chancellor for research , Tabriz University of Medical Sciences, Nutrition Research Center